This study performed a detailed comparative analysis of lncRNA PCAT14 and prostate cancer-related clinical indicators (age, race, diagnostic validity, tumor-node-metastasis (TNM) staging, initial treatment outcome, residual tumor, PSA, Gleason score, and overall survival). This evidence concerns the gene PCAT14 and neoplasm.